Elena M. Santagostino
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 177 publications
Challenges and Opportunities in Post-Marketing Reporting of Factor VIII Inhibitors With Efanesoctocog Alfa.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: July 28, 2025
Outcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysis.
Journal: Therapeutic advances in hematology
Published: May 21, 2025
A phase 1, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type 2N or type 3 von Willebrand disease.
Journal: Journal of thrombosis and haemostasis : JTH
Published: February 26, 2025
Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe hemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial.
Journal: Journal of thrombosis and haemostasis : JTH
Published: February 06, 2025
Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND-1 and XTEND-Kids Studies.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: November 14, 2024
Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life.
Journal: Journal of clinical medicine
Published: July 30, 2024
Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France.
Journal: Therapeutic advances in hematology
Published: July 19, 2024
Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.
Journal: The New England journal of medicine
Published: July 17, 2024
Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany.
Journal: Research and practice in thrombosis and haemostasis
Published: December 18, 2023
A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trial.
Journal: Blood advances
Published: August 17, 2023
Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis.
Journal: Research and practice in thrombosis and haemostasis
Published: March 02, 2023
Last Updated: 09/26/2026